Sep-10 -

Gynecological Group / QoL

EORTC 55971 – Randomized Phase III study comparing upfront debulking surgery versus neo-adjuvant chemotherapy in patients with Stage IIIc or IV epithelial ovarian carcinoma.

EORTC found that in patients with stage IIIC or IV epithelial ovarian cancer, timing of surgery (before or after chemotherapy) did not affect survival or health-related quality of life (HRQOL) in these patients. This finding helps enable clinicians to provide evidence-based information to their patient to support decision making.

READ MORE

Go to Top